Moleculin Biotech, Inc. MBRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.15M | 9.13M | 9.12M | 8.87M | 8.90M |
| Depreciation & Amortization | 46.00K | 67.00K | 90.00K | 112.00K | 122.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.87M | 27.03M | 25.10M | 24.21M | 25.44M |
| Operating Income | -28.87M | -27.03M | -25.10M | -24.21M | -25.44M |
| Income Before Tax | -30.33M | -40.50M | -33.56M | -55.70M | -37.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.33 | -40.50 | -33.56 | -55.70 | -37.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.33M | -40.50M | -33.56M | -55.70M | -37.32M |
| EBIT | -28.87M | -27.03M | -25.10M | -24.21M | -25.44M |
| EBITDA | -28.83M | -26.97M | -25.01M | -24.10M | -25.32M |
| EPS Basic | -301.32 | -846.78 | -1.09K | -1.88K | -1.54K |
| Normalized Basic EPS | -181.67 | -523.31 | -681.83 | -1.18K | -964.21 |
| EPS Diluted | -301.32 | -846.78 | -1.09K | -1.88K | -1.54K |
| Normalized Diluted EPS | -181.67 | -523.31 | -681.83 | -1.18K | -964.21 |
| Average Basic Shares Outstanding | 676.70K | 423.80K | 236.30K | 134.50K | 59.90K |
| Average Diluted Shares Outstanding | 676.70K | 423.80K | 236.30K | 134.50K | 59.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |